Arcturus Therapeutics
Logotype for Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics (ARCT) investor relations material

Arcturus Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Arcturus Therapeutics Holdings Inc
3rd Annual Guggenheim Healthcare Innovation Conference summary9 Nov, 2026

2027 catalysts and plans

  • Two mRNA programs have data catalysts in 2027: CF full phase II cohort 4 data in Q2; ARCT-2601 OTC deficiency top-line data in H2.

  • CF cohort 4 enrollment is continuing through year-end 2026; full data are targeted for Q2 2027, with top-line data expected in between and shared alongside the phase III decision.

  • If the CF program advances to phase III, Thermo Fisher is expected to contribute up to $40 million; preparation for the trial began in July 2026.

  • ARCT-2601 clinical trial startup is anticipated in early 2027; initial data from the reformulated candidate are expected in H2 2027.

LUNAR platform and pipeline

  • LUNAR is the lipid nanoparticle delivery technology; LUNAR 1.0 has established safety, tolerability and efficacy in an approved COVID vaccine across 30+ countries and in an OTC deficiency program.

  • LUNAR 2.0 showed 38 times better performance than LUNAR 1.0 in primates; the formulation is being applied to OTC deficiency with a focus on less frequent dosing and greater convenience.

  • The reformulated OTC candidate may enable monthly, lower-dose administration at home instead of clinic dosing every two weeks; this is a proposed goal, subject to clinical results.

  • PKU has been added to the pipeline, with an IND targeted for H2 2027; LUNAR 2.0 is presented as enabling liver targets that previously required impractical dosing frequency.

Cystic fibrosis program

  • The inhaled mRNA therapy aims to produce new CFTR protein in lung cells, addressing Class I patients who lack a transporter; about 15% of the CF population do not benefit from modulators, with roughly half of that group Class I.

  • Earlier dose-ranging tested 5, 10 and 15 mg once daily for about four weeks; CT scans at 10 mg showed improvements in mucus plugging and airway obstruction.

  • The ongoing 12-week study uses 10 mg once daily, enrolling up to 20 patients in the U.S., Turkey and Israel; measures include spirometry, lung clearance index, quality-of-life assessments and high-resolution CT.

  • Eligibility was narrowed to 45%–85% predicted lung function, and screening-to-baseline reproducibility criteria were tightened to reduce measurement variability.

  • Phase III go/no-go will consider the totality of lung-function, imaging and quality-of-life data; stability or improvement versus expected decline would be viewed positively.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Arcturus Therapeutics earnings date

Logotype for Arcturus Therapeutics Holdings Inc
Q4 20262 Mar, 2027
Arcturus Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Arcturus Therapeutics earnings date

Logotype for Arcturus Therapeutics Holdings Inc
Q4 20262 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing RNA-based therapeutics for the treatment of infectious diseases, rare diseases, and other medical conditions. The company utilizes its proprietary self-amplifying mRNA technology and lipid nanoparticle delivery system to develop vaccines and therapies. Arcturus' pipeline includes treatments for diseases such as COVID-19 and other RNA-based therapies targeting unmet medical needs. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.